« Back
Home /
Lirafugratinib

Lirafugratinib

Manufacturer	MedChem Express
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Amount	5 mg
Item no.	HY-147250-5mg
Targets	EGFR
CASRN	2549174-42-5
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	Lirafugratinib (RLY-4008) is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib covalently binds to Cys491. Lirafugratinib targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	509.53
Clinical_Information	Phase 2
Manufacturers Research_Area	Cancer
Solubility	DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturers Target	FGFR
Isoform	FGFR2
Pathway	Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5 mg

available

Request delivery time